VEVYE Drug Patent Profile
✉ Email this page to a colleague
When do Vevye patents expire, and what generic alternatives are available?
Vevye is a drug marketed by Harrow Eye and is included in one NDA. There are four patents protecting this drug.
This drug has eighty patent family members in nineteen countries.
The generic ingredient in VEVYE is cyclosporine. There are eighteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vevye
A generic version of VEVYE was approved as cyclosporine by HIKMA on October 29th, 1999.
Summary for VEVYE
| International Patents: | 80 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VEVYE |
| What excipients (inactive ingredients) are in VEVYE? | VEVYE excipients list |
| DailyMed Link: | VEVYE at DailyMed |
Pharmacology for VEVYE
| Drug Class | Calcineurin Inhibitor Immunosuppressant |
| Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
US Patents and Regulatory Information for VEVYE
VEVYE is protected by four US patents and one FDA Regulatory Exclusivity.
Patents protecting VEVYE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF DRY EYE DISEASE (DED)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting VEVYE
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VEVYE
See the table below for patents covering VEVYE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 3036306 | COMPOSITIONS OPHTALMIQUES CONTENANT DE LA CYCLOSPORINE (OPHTHALMIC COMPOSITIONS COMPRISING CICLOSPORIN) | ⤷ Try a Trial |
| European Patent Office | 3515467 | COMPOSITIONS OPHTALMIQUES CONTENANT DE LA CYCLOSPORINE (OPHTHALMIC COMPOSITIONS COMPRISING CICLOSPORIN) | ⤷ Try a Trial |
| Poland | 3722274 | ⤷ Try a Trial | |
| Australia | 2020205239 | Semifluorinated compounds for ophthalmic administration | ⤷ Try a Trial |
| Japan | 6397472 | ⤷ Try a Trial | |
| Mexico | 2020001408 | COMPUESTOS SEMIFLUORADOS PARA ADMINISTRACIÓN OFTÁLMICA. (SEMIFLUORINATED COMPOUNDS FOR OPHTHALMIC ADMINISTRATION.) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VEVYE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2049079 | LUC00006 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
